- Home
- MYGN vs OI Comparison
MYGN vs OI Comparison
Compare MYGN & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- OI
- Stock Information
- Founded
- MYGN 1991
- OI 1903
- Country
- MYGN United States
- OI United States
- Employees
- MYGN N/A
- OI N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- OI Containers/Packaging
- Sector
- MYGN Health Care
- OI Consumer Discretionary
- Exchange
- MYGN Nasdaq
- OI Nasdaq
- Market Cap
- MYGN 744.7M
- OI 2.2B
- IPO Year
- MYGN 1995
- OI N/A
- Fundamental
- Price
- MYGN $5.34
- OI $15.41
- Analyst Decision
- MYGN Hold
- OI Buy
- Analyst Count
- MYGN 15
- OI 8
- Target Price
- MYGN $15.14
- OI $17.13
- AVG Volume (30 Days)
- MYGN 1.4M
- OI 1.9M
- Earning Date
- MYGN 08-05-2025
- OI 07-29-2025
- Dividend Yield
- MYGN N/A
- OI N/A
- EPS Growth
- MYGN N/A
- OI N/A
- EPS
- MYGN N/A
- OI N/A
- Revenue
- MYGN $831,300,000.00
- OI $6,505,000,000.00
- Revenue This Year
- MYGN N/A
- OI $2.05
- Revenue Next Year
- MYGN $6.68
- OI $1.35
- P/E Ratio
- MYGN N/A
- OI N/A
- Revenue Growth
- MYGN 7.38
- OI N/A
- 52 Week Low
- MYGN $3.81
- OI $9.23
- 52 Week High
- MYGN $29.30
- OI $16.04
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- OI 62.49
- Support Level
- MYGN $4.90
- OI $15.07
- Resistance Level
- MYGN $5.83
- OI $15.88
- Average True Range (ATR)
- MYGN 0.28
- OI 0.47
- MACD
- MYGN 0.04
- OI 0.01
- Stochastic Oscillator
- MYGN 54.21
- OI 69.62
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.